
-
China property giant Vanke reports annual loss of $6.8 bn
-
World economies brace for Trump tariffs ahead of deadline
-
Myanmar declares week of mourning as quake toll passes 2,000
-
Japan leads hefty global stock market losses on tariff fears
-
Yes, oui, Cannes! Glamour name eyes place in French Cup final
-
'Different energy' at Man Utd after mini-revival, says Amorim
-
Fear of aftershocks in Myanmar forces patients into hospital car park
-
Far-right leaders rally around France's Le Pen after election ban
-
Renault and Nissan shift gears on alliance
-
Hard-hitting drama 'Adolescence' to be shown in UK schools
-
Primark boss resigns after inappropriate behaviour allegation
-
Myanmar declares week of mourning as quake toll passes 2,000, hopes fade for survivors
-
Mbappe can be Real Madrid 'legend' like Ronaldo: Ancelotti
-
Saka 'ready to go' for Arsenal after long injury lay-off: Arteta
-
Aston Martin to sell stake in Formula One team
-
Three talking points ahead of clay-court season
-
French court hands Le Pen five-year election ban
-
Probe accuses ex J-pop star Nakai of sexual assault
-
Japan leads hefty global stock market losses on tariff woes
-
Saka 'ready to go' after long injury lay-off: Arteta
-
Ingebrigtsen Sr, on trial for abusing Olympic champion, says he was 'overly protective'
-
Tourists and locals enjoy 'ephemeral' Tokyo cherry blossoms
-
Khamenei warns of 'strong' response if Iran attacked
-
France fines Apple 150 million euros over privacy feature
-
UK PM urges nations to smash migrant smuggling gangs 'once and for all'
-
Thai authorities probe collapse at quake-hit construction site
-
France's Le Pen convicted in fake jobs trial
-
Chinese tech giant Huawei says profits fell 28% last year
-
Trump says confident of TikTok deal before deadline
-
Myanmar declares week of mourning as hopes fade for quake survivors
-
Japan's Nikkei leads hefty market losses, gold hits record
-
Tears in Taiwan for relatives hit by Myanmar quake
-
Venezuela says US revoked transnational oil, gas company licenses
-
'Devastated': Relatives await news from Bangkok building collapse
-
Arsenal, Tottenham to play pre-season North London derby in Hong Kong
-
Japan's Nikkei leads hefty equity market losses; gold hits record
-
Israel's Netanyahu picks new security chief, defying legal challenge
-
Trump says US tariffs to hit 'all countries'
-
Prayers and tears for Eid in quake-hit Mandalay
-
After flops, movie industry targets fresh start at CinemaCon
-
Tsunoda targets podium finish in Japan after 'unreal' Red Bull move
-
French chefs await new Michelin guide
-
UK imposes travel permit on Europeans from Wednesday
-
At his academy, Romanian legend Hagi shapes future champions
-
Referee's lunch break saved Miami winner Mensik from early exit
-
Djokovic refuses to discuss eye ailment after shock Miami loss
-
Mitchell magic as Cavs bag 60th win, Pistons and T'Wolves brawl
-
Mensik shocks Djokovic to win Miami Open
-
Duterte lawyer: 'compelling' grounds to throw case out
-
What happens on Trump's 'Liberation Day' and beyond?
RYCEF | -2.59% | 9.66 | $ | |
CMSC | -0.21% | 22.415 | $ | |
RBGPF | 1.47% | 68 | $ | |
GSK | -1.77% | 38.065 | $ | |
SCS | 0.27% | 11.13 | $ | |
BCC | -0.66% | 97.655 | $ | |
NGG | -0.06% | 65.53 | $ | |
RIO | -2.74% | 59.4 | $ | |
VOD | -0.69% | 9.385 | $ | |
RELX | -0.08% | 50.12 | $ | |
AZN | -1.71% | 72.55 | $ | |
JRI | 0.46% | 12.93 | $ | |
CMSD | -0.31% | 22.64 | $ | |
BTI | 1.52% | 41.135 | $ | |
BCE | 1.1% | 23.225 | $ | |
BP | 0.37% | 33.985 | $ |

Moderna Covid vaccine gets full US approval
The US Food and Drug Administration (FDA) announced Monday that it has granted full approval to Moderna's Covid-19 "Spikevax" vaccine, which had previously received an emergency use authorization in the United States.
"The public can be assured that Spikevax meets the FDA's high standards for safety, effectiveness and manufacturing quality required of any vaccine approved for use in the United States," acting FDA commissioner Janet Woodcock said in a statement.
"The FDA's approval of Spikevax is a significant step in the fight against the Covid-19 pandemic, marking the second vaccine approved to prevent Covid-19," Woodcock said.
The full approval of the Moderna vaccine is for individuals aged 18 or older.
A Pfizer vaccine for individuals aged 16 or older received full FDA approval at the end of August.
Woodcock said she hoped FDA approval of the Moderna vaccine "may instill additional confidence in making the decision to get vaccinated."
Moderna CEO Stephane Bancel called the FDA move a "momentous milestone" for the company.
"Our Covid-19 vaccine has been administered to hundreds of millions of people around the world, protecting people from Covid-19 infection, hospitalization and death," Bancel said in a statement.
The Moderna vaccine received an emergency use authorization in December 2020.
The full approval from the FDA concerns the first two doses of the Moderna vaccine. A booster dose remains under an emergency use authorization.
The FDA said clinical trials to determine the effectiveness of Spikevax included 14,287 vaccine recipients and 14,164 placebo recipients.
The most common side effects by clinical trial participants were pain at the injection site, fatigue, headaches, muscle or joint pain, chills, nausea or vomiting and swollen lymph nodes, the FDA said.
It said there was an increased risk in men aged 18 to 24 of myocarditis -- inflammation of the heart muscle -- and pericarditis -- inflammation of tissue surrounding the heart -- following vaccination with the second dose.
But, the FDA said, it has determined that the "benefits of the vaccine outweigh the risk of myocarditis and pericarditis in individuals 18 years of age and older."
S.F.Warren--AMWN